Ciprofibrate: Uses, Dosage, Side Effects & Precautions

Ciprofibrate is a lipid-lowering agent that belongs to the class of drugs known as fibrates. It is primarily used to treat hyperlipidemia, a condition characterized by elevated levels of lipids (fats) in the blood. Ciprofibrate helps to lower triglycerides, very-low-density lipoprotein (VLDL) cholesterol, and low-density lipoprotein (LDL) cholesterol while increasing high-density lipoprotein (HDL) cholesterol levels.

1. Introduction to Ciprofibrate

Ciprofibrate, also known as WIN 35,833, is a monocarboxylic acid derivative of the cyclopropane member of the organochlorine family. Its chemical formula is C13H14Cl2O3, and it belongs to the class of phenoxyacetic acid derivatives. Ciprofibrate is a lipid-lowering agent used to treat hyperlipidemia and reduce the risk of cardiovascular disease.

2. History and Development of Ciprofibrate

Ciprofibrate was patented in 1972 and gained approval for medical use in 1985. It was developed as a lipid-lowering agent to help manage hyperlipidemia and related conditions. Over the years, extensive research has been conducted to understand its mechanism of action, clinical efficacy, and safety profile.

3. Chemical Properties of Ciprofibrate

As a monocarboxylic acid, Ciprofibrate exhibits unique chemical properties that contribute to its pharmacological activity. Its cyclopropane structure and organochlorine nature further influence its interactions within the body. Additionally, Ciprofibrate is a member of the phenoxyacetic acid derivative family, which shares certain characteristics with other compounds in this class.

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624763/

4. Mechanism of Action of Ciprofibrate

Ciprofibrate exerts its lipid-lowering effects by interacting with peroxisome proliferator-activated receptors (PPARs), which are nuclear receptors that regulate the expression of genes involved in lipid and lipoprotein metabolism. By activating PPARs, Ciprofibrate modulates various biochemical pathways, leading to changes in lipoprotein synthesis, lipid transport, and lipid utilization.

Source: https://www.nature.com/articles/s41598-018-22388-3

5. Pharmacological Profile of Ciprofibrate

Ciprofibrate exhibits unique pharmacokinetic properties, including its absorption, distribution, metabolism, and excretion within the body. It has a relatively short time to reach maximum serum concentration, and its metabolism and excretion pathways have been extensively studied. Understanding the pharmacological profile of Ciprofibrate is crucial for optimizing its therapeutic use and minimizing potential adverse effects.

Source: https://pubmed.ncbi.nlm.nih.gov/28287107/

6. Clinical Uses of Ciprofibrate

The primary clinical use of Ciprofibrate is as a lipid-lowering agent for the treatment of hyperlipidemia. It is particularly effective in reducing serum triglycerides, VLDL cholesterol, and LDL cholesterol levels, while also increasing HDL cholesterol levels. Ciprofibrate is used in conjunction with a low-fat diet and lifestyle modifications to manage hyperlipidemia and reduce the risk of cardiovascular disease.

7. Dosage and Administration of Ciprofibrate

The standard dosage of Ciprofibrate is 100mg tablets taken orally once daily. It is recommended to take Ciprofibrate with or after meals to enhance absorption. Patients are advised to follow a low-fat diet and engage in regular physical activity while taking Ciprofibrate to maximize its lipid-lowering effects.

8. Adverse Effects and Contraindications of Ciprofibrate

Like other medications, Ciprofibrate may cause certain side effects. Common adverse effects include gastrointestinal disturbances, headache, and skin rash. More severe reactions, such as muscle weakness, liver dysfunction, and gallstones, have been reported in some cases. Ciprofibrate is contraindicated in patients with severe liver or kidney disease, and caution is advised in those with a history of gallbladder disease.

Source: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019576s040s041lbl.pdf

9. Interactions of Ciprofibrate with Other Drugs

Ciprofibrate may interact with certain medications, potentially altering their effects or increasing the risk of adverse reactions. Potential drug- drug interactions include those with anticoagulants, immunosuppressants, and certain antidiabetic agents. It is crucial for patients to inform their healthcare providers about all medications they are taking to avoid harmful interactions.

Source: https://www.drugs.com/drug-interactions/ciprofibrate.html

10. Patient Information for Ciprofibrate

Patients taking Ciprofibrate should be provided with comprehensive information about the medication, including its intended use, proper administration, potential side effects, and precautions. It is essential for patients to follow the instructions provided by their healthcare providers and to report any adverse reactions or concerns promptly.

11. Research and Studies on Ciprofibrate

Numerous scientific studies have been conducted to investigate the efficacy, safety, and mechanisms of action of Ciprofibrate. Clinical trials have evaluated its effectiveness in lowering lipid levels and reducing cardiovascular risk factors. Ongoing research areas include exploring potential applications of Ciprofibrate in other metabolic disorders and understanding its molecular pathways in greater detail.

Source: https://pubmed.ncbi.nlm.nih.gov/32567880/

12. International Perspectives on Ciprofibrate

Ciprofibrate has been approved for use in various countries around the world, although its availability and regulatory status may vary. In some regions, it is widely used as a lipid-lowering agent, while in others, it may be less prevalent or subject to different guidelines and restrictions.

13. Regulatory and Safety Information for Ciprofibrate

Ciprofibrate is assigned the following regulatory identifiers:- CAS Number: 52214-84-3- EC Number: 257-744-6- MDL Number: MFCD00467135- PubChem Substance ID: 24856728

14. Ciprofibrate in Comparative Context

Ciprofibrate belongs to the class of fibrates, which includes other lipid-lowering agents such as gemfibrozil and fenofibrate. While sharing some common features, Ciprofibrate has unique characteristics in terms of its chemical structure, pharmacokinetic properties, and potential advantages or disadvantages compared to other fibrates.

15. Commercial Information about Ciprofibrate

Ciprofibrate is available under various brand names in different regions, such as Modalim, Penirium, and Sorbucor. It is manufactured and supplied by several pharmaceutical companies around the world, catering to the demand for lipid-lowering therapies in various markets.